Chen Schor
Chen Schor's purchase track record
Chen Schor has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/28/2023 | ACET | $15K | +22.5% | +65.5% | +22.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Adicet Bio shares positive Phase 1 lupus data, Wedbush lifts target. Adicet Bio announced that its Phase 1 study of Prula‑cel in lupus patients showed positive safety and efficacy signals, and the company is moving forward with plans for a pivotal trial. Wedbush analysts kept an Outperform rating and raised their price target to $28, reflecting confidence in the data. The news comes as the stock trades near its 52‑week high, with analyst consensus targets averaging $34.83.
Transaction History
| KPTI | ▲ Buy | Grant | 15,508 | $0 | 5/21/2026 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 1,755 | $15K | 1/24/2026 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 28,101 | $26K | 1/24/2025 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 15,290 | $37K | 1/24/2024 | View on chart |
| ACET | ▲ Buy | Grant | 70,300 | $0 | 1/24/2024 | View on chart |
| ACET | ▲ Buy | Open Market | 5,500 | $7K | 10/2/2023 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 23,208 | $32K | 10/2/2023 | View on chart |
| ACET | ▼ Sell | Open Market | 5,500 | $7K | 9/29/2023 | View on chart |
| ACET | ▼ Sell | Open Market | 5,500 | $8K | 9/28/2023 | View on chart |
| ACET | ▲ Buy | Open Market | 5,500 | $8K | 9/28/2023 | View on chart |
| ACET | ▲ Buy | Grant | 85,500 | $0 | 1/24/2023 | View on chart |
| ACET | ▼ Sell | Open Market | 9,955 | $209K | 11/10/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 30,000 | $602K | 11/10/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 30,000 | $571K | 11/7/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 24,813 | $448K | 11/3/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 500 | $9K | 11/2/2022 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 21,288 | $303K | 10/4/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 952 | $17K | 9/14/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 3,371 | $61K | 9/13/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 66,747 | $1.1M | 9/12/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 200 | $4K | 9/12/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 8,094 | $134K | 9/9/2022 | View on chart |
| ACET | ▲ Buy | Grant | 48,000 | $0 | 8/4/2022 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 21,288 | $389K | 8/4/2022 | View on chart |
| ACET | ▼ Sell | Gift | 53,424 | $0 | 7/6/2022 | View on chart |
| ACET | ▼ Sell | Gift | 53,424 | $0 | 7/6/2022 | View on chart |
| ACET | ▲ Buy | Grant | 48,000 | $0 | 2/14/2022 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 21,288 | $304K | 2/14/2022 | View on chart |
| ACET | ▲ Buy | Grant | 48,000 | $0 | 1/28/2022 | View on chart |
| ACET | ▼ Sell | Tax Withholding | 21,288 | $249K | 1/28/2022 | View on chart |
| ACET | ▲ Buy | Grant | 240,000 | $0 | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Karyopharm Reports Inducement Grant Under Nasdaq Rule
Karyopharm Therapeutics disclosed an inducement grant made under Nasdaq Listing Rule 5635(c)(4). This type of disclosure is typically required when a company offers equity compensation to a new employee or consultant to induce them to join the firm. The announcement is a standard corporate compliance update rather than a change in business operations or financial results.
Karyopharm Reports Inducement Grant Under Nasdaq Rule. Karyopharm Therapeutics disclosed an inducement grant made under Nasdaq Listing Rule 5635(c)(4). This type of disclosure is typically required when a company offers equity compensation to a new employee or consultant to induce them to join the firm. The announcement is a standard corporate compliance update rather than a change in business operations or financial results.